Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03245541 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Sep 2026 → Sep 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Record History

  1. Primary and study completion pushed from Sep 2026 to Sep 2027 Eligibility criteria expanded, about 42 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 42 words
  2. Primary and study completion dates: Sep 2025 to Sep 2026v18
  3. Primary and study completion dates: Sep 2024 to Sep 2025v17
  4. 2 versions Re-verified since Aug 10, 2023, no change to tracked fieldsv15-v16
  5. Primary and study completion dates: Sep 2023 to Sep 2024 Study sites: 8 to 7v14 Show 1 more changeShow less
    • Study sites: 8 to 7
Show 12 earlier versionsHide 12 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 36 to confirmed 18 · Site details revised at 8 of 8 sitesv13 Show 2 more changesShow less
    • Enrollment target: estimated 36 to confirmed 18
    • Site details revised at 8 of 8 sites
  2. Re-verified, no change to tracked fieldsv12
  3. Primary and study completion dates: Sep 2022 to Sep 2023v11
  4. Re-verified, no change to tracked fieldsv10
  5. Eligibility criteria expanded, about 29 wordsv9 See this version in full on ClinicalTrials.gov ↗
  6. Site contacts updated at 7 of 8 sitesv8
  7. Lead sponsor: Cedars-Sinai Medical Center to Memorial Sloan Kettering Cancer Center Trial status: Suspended to Recruiting · Primary completion date: Sep 2021 to Sep 2022 · Start date: Aug 22, 2017 to Aug 14, 2020 · 8 morev7 Show 11 more changesShow less
    • Trial status: Suspended to Recruiting
    • Primary completion date: Sep 2021 to Sep 2022
    • Start date: Aug 22, 2017 to Aug 14, 2020
    • Primary endpoints: 3 to 4
    • Enrollment target: 30 to 36
    • Study sites: 1 to 8
    • Interventions: Durvalumab (Drug), Stereotactive Ablative Body Radiotherapy (Radiation) to Durvalumab (Drug), Stereotactic Ablative Body Radiotherapy (SABR) (Radiation)
    • Eligibility criteria expanded, about 176 words
    • Study description shortened, about 273 words
    • Collaborators: 1 to 2
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  8. 2 versions Re-verified since Jul 1, 2019, no change to tracked fieldsv5-v6
  9. Trial status: Recruiting to Suspended Sponsor's reason: Pending amendment Completion date: Sep 2021 to Sep 2022 · Site details revisedv4 Show 2 more changesShow less
    • Completion date: Sep 2021 to Sep 2022
    • Site details revised
  10. Eligibility criteria expanded, about 31 words Site contact updatedv3 Show 1 more changeShow less
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  11. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Sep 2017 to Aug 22, 2017 · Interventions: Durvalumab (Drug) to Durvalumab (Drug), Stereotactive Ablative Body Radiotherapy (Radiation) · 1 morev2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2017 to Aug 22, 2017
    • Interventions: Durvalumab (Drug) to Durvalumab (Drug), Stereotactive Ablative Body Radiotherapy (Radiation)
    • Study description expanded, about 273 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out if combining durvalumab with standard stereotactic ablative radiotherapy (SABR) is an effective treatment for people with locally advanced or borderline resectable pancreatic cancer. The researchers will also look at the safety of the combination treatment and any side effects it causes.
Trial Details
NCT Number NCT03245541
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: AstraZeneca, Cedars-Sinai Medical Center
Conditions Pancreatic Adenocarcinoma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov